GreenAJGelfandJMCreeBA, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet2017; 390(10111): 2481–2489. DOI: 10.1016/S0140-6736(17)32346-2.
2.
BrownJWLCunniffeNGPradosF, et al. Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): A randomised, double-blind, placebo-controlled, parallel-group, phase 2a study. Lancet Neurol2021; 20(9): 709–720. DOI: 10.1016/S1474-4422(21)00179-4.
3.
CordanoCSinJHTimmonsG, et al. Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy. Brain2022; 145(11): 3943–3952. DOI: 10.1093/brain/awac207.
4.
DuncanGJIngramSDEmberleyK, et al. Remyelination protects neurons from DLK-mediated neurodegeneration. Nat Commun2024; 15(1): 9148. DOI: 10.1038/s41467-024-53429-5.
5.
Riboni-VerriGGautamRChenB, et al. Myelination of the retinal nerve fibre layer: A case report. MSJ2026; 32(3): 347–350.
